Guangzhou LBP Medicine Science & Technology Co (688393) Fair Value & Analysis
Healthcare · CN · Market cap 1.9B CNY
Fair value as of: Jun 24, 2026
Analysis
Guangzhou LBP Medicine Science & Technology Co (688393) currently trades at ¥19.13, while our model-based Fair Value estimate is ¥5.44 — implying the stock looks roughly 71.6% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample preservation solutions, and automatic nucleic acid molecular hybridization instruments; fluorescence in situ hybridization products comprising auto-fish instruments, and AML1/ETO, EGFR, BCR/ABL fusion, PML/RARA, and TOP2A gene testing kits; and digital pathology products pathological medical image analysis processing systems, real-time microscopic visual field sharing systems, and bingli scanner. It also provides immunohistochemistry products including automatic antigen repair instrument and automatic immunocytoche…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Guangzhou LBP Medicine Science & Technology Co (688393) undervalued?
What is the fair value of 688393?
What is the quality score of 688393?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.